NurExone Announces the Transfer of Manufacturing of the Active Element in ExoPTEN Drug to a Commercial GMP Manufacturer
TORONTO and HAIFA, Israel, Aug. 01, 2024 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX), (OTCQB:NRXBF), (Germany: J90) (the “Company” or “NurExone”), a pioneering biopharmaceutical company, is thrilled to announce an important milestone in its regenerative medicine efforts. The Company has successfully transferred the manufacturing of the small interfering RNA (“siRNA”) sequence for its flagship ExoPTEN nanodrug to a German producer with Good Manufacturing Practice (“GMP”) capabilities. A move to a GMP-grade manufacturer is essential for producing a drug for clinical trials and commercial sale.
Related news for (NRXBF)
- NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update
- NurExone Biologic Inc. Announces Fourth Quarter and Full-Year 2024 Financial Results and Provides Corporate Update
- NurExone Biologic Announces U.S. Uplisting Intention and Closes C$2.3 Million Private Placement
- NurExone Biologic Recognized as a 2025 TSX Venture 50(TM) Top Performing Stock
- NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award